Vascular surgical devices provider LeMaitre Q3 sales miss estimates

Lemaitre Vascular

06/11/2025 22:01

Overview

LeMaitre Q3 sales grow 11% but miss analyst expectations

Adjusted EPS for Q3 rises 27%, driven by organic growth in grafts and shunts

Company announces $0.20/share dividend

Outlook

LeMaitre Vascular projects Q4 sales between $61.8 mln and $63.8 mln

Company expects full-year sales of $247 mln to $249 mln

LeMaitre Vascular forecasts Q4 EPS between $0.64 and $0.69

Result Drivers

GRAFTS AND SHUNTS - Sales growth driven by strong performance in grafts (+23%) and shunts (+18%)

ARTEGRAFT LAUNCH - Artegraft's international launch accelerated growth, contributing to a 33% increase

HIGHER SELLING PRICES - Adjusted gross margin increased due to higher average selling prices and manufacturing efficiencies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Miss
$61.05 mln
$62.17 mln (11 Analysts)
Q3 Net Income
$17.36 mln
Q3 Gross Profit
$45.96 mln
Q3 Income From Operations
$20.31 mln
Q3 Pretax Profit
$22.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for LeMaitre Vascular Inc is $108.00, about 20.1% above its November 5 closing price of $86.27

The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release: ID:nGNX8S3Ctb

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)